Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01970787 · ClinicalTrials.gov registry record · NA
A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System
A NA study, sponsored by Medtronic - MITG.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT01970787 is a NA study that has completed, run by Medtronic - MITG. The registered enrollment target is 22 participants.
The verdict
NCT01970787, a NA study, has completed, sponsored by Medtronic - MITG.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Single-center prospective pilot trial involving up to 22 subjects. This study will assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal canal using the FDA cleared HALO Ablation System to eradicate anal HSIL lesions in HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN). The study intervention will demonstrate that a reasonable proportion of subjects will be histologically cleared of their anal HSIL within the ETZ in a tolerable and relatively safe manner
Interventions
- DEVICE Radiofrequency Ablation (RFA) using the HALO Ablation System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01970787
The ClinicalTrials.gov registry entry for NCT01970787 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Radiofrequency Ablation (RFA) using the HALO Ablation System is the first listed.
NCT01970787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01970787 about?
NCT01970787 is a clinical study titled "A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System". This is a Single-center prospective pilot trial involving up to 22 subjects. This study will assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal canal using the FDA cleared HALO Ablation System to eradicate anal HSIL lesions in HIV-negative subjects with intra-a...
What is the current status of trial NCT01970787?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2013-03. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01970787?
The interventions under investigation include: Radiofrequency Ablation (RFA) using the HALO Ablation System (DEVICE).
Who is sponsoring clinical trial NCT01970787?
This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.